Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts. Show more

Location: 852 Winter Street, Waltham, MA, 02451, United States | Website: https://zenasbio.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

851.9M

52 Wk Range

$5.83 - $26.25

Previous Close

$20.23

Open

$20.39

Volume

231,617

Day Range

$20.31 - $22.18

Enterprise Value

579.6M

Cash

273.3M

Avg Qtr Burn

-37.1M

Insider Ownership

21.06%

Institutional Own.

78.01%

Qtr Updated

06/30/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Obexelimab (CD19xFcyRIIb) Details IgG4-related disease Suspected Mover™ Susp. Mover™	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Obexelimab (CD19xFcyRIIb) Details Systemic lupus erythematosus	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Obexelimab (CD19xFcyRIIb) Details Multiple sclerosis	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Obexelimab (CD19xFcyRIIb) Details Warm autoimmune hemolytic anemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.